



INTERNÍ
KARDIOLOGICKÁ
KLINIKA FN BRNO a LF MU

ECG monitoring after Covid - 19

G. Matejová, M. Radvan, L. Koc, M. Kameník, R. Štěpánková, P. Kala

*Department of Internal Medicine and Cardiology, University Hospital Brno
and Faculty of Medicine of Masaryk University, Brno, Czech Republic*

Department of Health Sciences Masaryk University

CoSuBr (Covid survivals in Brno) - Methods



- Prospective observational cohort study
- March 2020 - January 2021
- Positive PCR swab test – alpha and beta variants
- 1 year of follow up
- 3 Visits (**V1**- 6 weeks, **V2**- 6 months, **V3**- 1 year)
- Demographic parameters, clinical evaluation
- Echocardiography
- 7- days ECG monitoring
- Spirometry
- Laboratory parameters

Aims





- To evaluate cardiovascular risks and the need of systematic cardiovascular screening in patients recovered from Covid -19

Results



- 106 patients
- **84 (79%)** patients had all three visits
- Mean age 47,5 years (18-77)



Results - Acute phase



- **26** patients (24,6%) were hospitalized due to acute infection, **12** of them at ICU


Acute infection	n (%)
Asymptomatic	1 (1)
Mild (flu like symptoms, anosmia)	77 (73,3)
Moderate (pneumonia, no O2)	5 (4,8)
Severe (pneumonia with O2)	19 (18,1)
Critical (nasal high flow, NIV, UPV, ECMO)	3 (2,9)

Results - Persisting symptoms



- **More than half of patient** suffered from persisting symptoms of the disease at all three visits V1, V2 and V3

Persisting symptoms (%)		
V1	V2	V3
64,20%	72,30%	62,70%



- More than half of the whole group (50.9%) mentioned **at least one symptom of possible cardiac origin** (breathing problems, palpitations, exercise intolerance, fatigue)

Results - Persisting symptoms



Persisting symptoms	V1 (%)*	V3 (%)*
Fatigue	53,2	57,7
Dyspnea	35,5	31,4
Loss of smell	32	27,5
Loss of taste	19	23
Cough	17,7	19,6
Cefalea	6,5	33
Nausea	1,6	3,9

* percentages are calculated from the total number of patients

Results 7- days ECG monitoring



	V1 mean \pm SD	V3 mean \pm SD	p		V1 mean \pm SD	V3 mean \pm SD	p
Afib, flutter	0	0,8 \pm 0,7	1	Max. HR	154,5 \pm 21,6	151,7 \pm 21,2	0,186
SVT non-sustained	9,8 \pm 2,9	15 \pm 5,0	0,800	Min. HR	44,9 \pm 6,2	45 \pm 5,2	0,982
PACs	1142 \pm 422,5	1278,9 \pm 426,2	0,790	Mean HR	72,7 \pm 8,5	72,5 \pm 8,6	0,756
PACs couplets	24,9 \pm 9,8	23,8 \pm 8,7	0,043				
PVCs isolated	482 \pm 221,4	941 \pm 545,1	0,965				
PVCs couplets	2,9 \pm 1,7	1,6 \pm 0,03	0,674				
PVCs bigeminy	2,3 \pm 1,2	16 \pm 11,6	0,984				
VT non-sustained	0,2 \pm 0,05	0,4 \pm 0,09	0,127				

- No marked differences in arrhythmias occurrence between V1 and V3

Results 7- days ECG monitoring



Presence of detected significant pathology **was rare:**

- One **paroxysmal atrial fibrillation** in 73-years old woman with dilated left atrium
- One **AV blockade II** with indication for implantation of the pacemaker in 71-years old man

No cardiac MRI findings of myocardial inflammation

In both cases no clear relationship to previous SARS-CoV-2 infection

Results 7- days ECG monitoring



	V1 mean \pm SD	V3 mean \pm SD	p
HF	341,5 \pm 334,9	268 \pm 266,3	0,032
LF	718,8 \pm 433,7	646,8 \pm 361	0,024
rMSSD	33 \pm 13,9	30,6 \pm 12,8	0,175
pNN50	10,8 \pm 9,28	9,3 \pm 8,7	0,255
SDNN	156,6 \pm 40,6	156 \pm 38,2	0,855
SDDN index	59,5 \pm 18	55,8 \pm 15,7	0,036
Triangle	28,5 \pm 7,8	29,5 \pm 8,8	0,488

During one year of follow up after COVID-19 infection we have found statistically significant changes in HF and LF bands

These parameters are mostly affected by breathing rate and are suggesting possible autonomic dysregulation (HF/LF ratio) or could be just collateral chance finding

Conclusion



- Our study **did not find an increased risk** of development of arrhythmias after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) even in a population with high proportion of ongoing symptomatology
- Our data suggest there is no need for systematic cardiovascular screening in patients recovered from Covid -19



INTERNÍ
KARDIOLOGICKÁ
KLINIKA FN BRNO a LF MU

Thank You for attention

Supported by project nr. LX22NPO5107 (MEYS): Funded by European Union – Next Generation EU and by
MH CZ - DRO (FNBr, 65269705)